Trial Outcomes & Findings for Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? (NCT NCT01964404)

NCT ID: NCT01964404

Last Updated: 2025-12-09

Results Overview

Activation of the Brain Reward Circuit (particularly the nucleus accumbens) in anticipation of monetary reward. The 'Measure' is a mean of the Fisher-Z transform of the inter-regional correlation measured for each participant between the nucleus accumbens and anterior cingulate cortex. The Fisher-transformation creates a normally distributed correlation value for statistical analyses assessing between group differences. A Fisher-Z transform of '0' represents a value of '0' for the estimated correlation, which represents no correlation in the activity time series between the regions. The values reflect strengths of functional connectivity between brain regions that can be compared between groups (e.g. Healthy controls and SCZ-CUD groups who received different study drugs). Means and standard deviations similar to healthy controls would be considered a good outcome.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

263 participants

Primary outcome timeframe

3 hours

Results posted on

2025-12-09

Participant Flow

Participant milestones

Participant milestones
Measure	Cannabis Use Disorder Participants met criteria for Cannabis Use Disorder (CUD)	Dual Diagnosis (Schizophrenia and Cannabis Use Disorder) Participants with a Dual Diagnosis of Schizophrenia and Cannabis Use Disorder	Schizophrenia Participants diagnosed with Schizophrenia	Healthy Controls Participants with no mental health diagnosis or cannabis use	Marijuana Cigarette and Placebo Capsule CUD Only Participants with Cannabis Use Disorder (CUD) and randomized to receive Marijuana Cigarette and Placebo Capsule	Dronabinol and Placebo Cigarette CUD Only Participants met criteria for Cannabis Use Disorder (CUD) and were randomized to Dronabinol and Placebo Cigarette	Placebo Cigarette and Placebo Capsule CUD Only Participants with a diagnosis of Cannabis Use Disorder (CUD) randomized to Placebo Dronabinol and Placebo Cigarette	Marijuana Cigarette and Placebo Capsule - SCZ-CUD Participants with Dual Diagnosis of Schizophrenia and Cannabis Use Disorder (SCZ-CUD) and randomized to Marijuana Cigarette and Placebo Capsule - SCZ-CUD	Dronabinol and Placebo Cigarette - SCZ-CUD Participants diagnosed with Diagnosis Schizophrenia and Cannabis Use Disorder and randomized to Dronabinol and Placebo Cigarette	Placebo Cigarette and Placebo Capsule - SCZ-CUD Participants diagnosed with Schizophrenia and Cannabis Use Disorder and randomized to placebo Cigarette and Placebo Capsule
Pre-Randomization - Scan 1 STARTED	111	79	33	40	0	0	0	0	0	0
Pre-Randomization - Scan 1 Enrolled and Completed Neuropsych Testing	62	43	21	31	0	0	0	0	0	0
Pre-Randomization - Scan 1 Completed Scan 1	54	35	18	28	0	0	0	0	0	0
Pre-Randomization - Scan 1 COMPLETED	51	34	18	27	0	0	0	0	0	0
Pre-Randomization - Scan 1 NOT COMPLETED	60	45	15	13	0	0	0	0	0	0
Randomization - Scan 2 STARTED	0	0	18	27	17	17	17	11	12	11
Randomization - Scan 2 COMPLETED	0	0	18	27	17	17	17	11	12	11
Randomization - Scan 2 NOT COMPLETED	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Cannabis Use Disorder Participants met criteria for Cannabis Use Disorder (CUD)	Dual Diagnosis (Schizophrenia and Cannabis Use Disorder) Participants with a Dual Diagnosis of Schizophrenia and Cannabis Use Disorder	Schizophrenia Participants diagnosed with Schizophrenia	Healthy Controls Participants with no mental health diagnosis or cannabis use	Marijuana Cigarette and Placebo Capsule CUD Only Participants with Cannabis Use Disorder (CUD) and randomized to receive Marijuana Cigarette and Placebo Capsule	Dronabinol and Placebo Cigarette CUD Only Participants met criteria for Cannabis Use Disorder (CUD) and were randomized to Dronabinol and Placebo Cigarette	Placebo Cigarette and Placebo Capsule CUD Only Participants with a diagnosis of Cannabis Use Disorder (CUD) randomized to Placebo Dronabinol and Placebo Cigarette	Marijuana Cigarette and Placebo Capsule - SCZ-CUD Participants with Dual Diagnosis of Schizophrenia and Cannabis Use Disorder (SCZ-CUD) and randomized to Marijuana Cigarette and Placebo Capsule - SCZ-CUD	Dronabinol and Placebo Cigarette - SCZ-CUD Participants diagnosed with Diagnosis Schizophrenia and Cannabis Use Disorder and randomized to Dronabinol and Placebo Cigarette	Placebo Cigarette and Placebo Capsule - SCZ-CUD Participants diagnosed with Schizophrenia and Cannabis Use Disorder and randomized to placebo Cigarette and Placebo Capsule
Pre-Randomization - Scan 1 Screen Fail	49	36	12	9	0	0	0	0	0	0
Pre-Randomization - Scan 1 Withdrawal by Subject	3	1	0	1	0	0	0	0	0	0

Baseline Characteristics

Measure only collected for subjects with SCZ and SCZ-CUD

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Marijuana Cigarette and Placebo Capsule SCZ-CUD n=11 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and Placebo Cigarette SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo Cigarette and Placebo Capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ-CUD Not Randomized n=8 Participants Dual diagnosis of Schizophrenia and Cannabis Use disorder, - Completed Scan 1 but not Randomized	Marijuana Cigarette and Placebo Capsule CUD Only n=17 Participants CUD only 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant	Dronabinol and Placebo Cigarette CUD Only n=17 Participants CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.	Placebo Cigarette and Placebo Capsule CUD Only n=17 Participants CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.	Cannabis Use Disorder - CUD Did Not Randomize n=10 Participants Cannabis Use Disorder (CUD), Completed Scan 1 but not Randomized	SCZ Only n=18 Participants No drug intervention - Completed Scan 1 and 2	SCZ Only - Did Not Complete Scan 2 n=3 Participants No drug intervention - Completed Scan 1 but not Scan 2	Healthy Control - n=27 Participants No drug intervention - Completed Scan 1 and 2	Healthy Control - Did Not Complete Scan 2 n=4 Participants No drug intervention - Completed Scan 1 but not Scan 2	Total n=155 Participants Total of all reporting groups
Age, Continuous	33.00 Years n=11 Participants	28.42 Years n=12 Participants	31.55 Years n=11 Participants	26.75 Years n=8 Participants	43.59 Years n=17 Participants	34.29 Years n=17 Participants	31.53 Years n=17 Participants	34.10 Years n=10 Participants	35.55 Years n=18 Participants	29.66 Years n=3 Participants	33.48 Years n=27 Participants	26.5 Years n=4 Participants	32.59 Years n=155 Participants
Sex: Female, Male Female	2 Participants n=11 Participants	3 Participants n=12 Participants	1 Participants n=11 Participants	3 Participants n=8 Participants	3 Participants n=17 Participants	2 Participants n=17 Participants	2 Participants n=17 Participants	1 Participants n=10 Participants	7 Participants n=18 Participants	1 Participants n=3 Participants	8 Participants n=27 Participants	2 Participants n=4 Participants	35 Participants n=155 Participants
Sex: Female, Male Male	9 Participants n=11 Participants	9 Participants n=12 Participants	10 Participants n=11 Participants	5 Participants n=8 Participants	14 Participants n=17 Participants	15 Participants n=17 Participants	15 Participants n=17 Participants	9 Participants n=10 Participants	11 Participants n=18 Participants	2 Participants n=3 Participants	19 Participants n=27 Participants	2 Participants n=4 Participants	120 Participants n=155 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=11 Participants	1 Participants n=12 Participants	1 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	1 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	3 Participants n=155 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	11 Participants n=11 Participants	11 Participants n=12 Participants	10 Participants n=11 Participants	8 Participants n=8 Participants	17 Participants n=17 Participants	16 Participants n=17 Participants	17 Participants n=17 Participants	10 Participants n=10 Participants	18 Participants n=18 Participants	3 Participants n=3 Participants	27 Participants n=27 Participants	4 Participants n=4 Participants	152 Participants n=155 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=11 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	0 Participants n=155 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=11 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=8 Participants	1 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	1 Participants n=155 Participants
Race (NIH/OMB) Asian	0 Participants n=11 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	1 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	1 Participants n=27 Participants	0 Participants n=4 Participants	2 Participants n=155 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=11 Participants	1 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	2 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	3 Participants n=27 Participants	1 Participants n=4 Participants	7 Participants n=155 Participants
Race (NIH/OMB) Black or African American	2 Participants n=11 Participants	0 Participants n=12 Participants	1 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	2 Participants n=10 Participants	1 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	6 Participants n=155 Participants
Race (NIH/OMB) White	9 Participants n=11 Participants	10 Participants n=12 Participants	9 Participants n=11 Participants	8 Participants n=8 Participants	16 Participants n=17 Participants	15 Participants n=17 Participants	15 Participants n=17 Participants	7 Participants n=10 Participants	17 Participants n=18 Participants	3 Participants n=3 Participants	23 Participants n=27 Participants	3 Participants n=4 Participants	135 Participants n=155 Participants
Race (NIH/OMB) More than one race	0 Participants n=11 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=17 Participants	0 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	0 Participants n=155 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=11 Participants	1 Participants n=12 Participants	1 Participants n=11 Participants	0 Participants n=8 Participants	0 Participants n=17 Participants	1 Participants n=17 Participants	0 Participants n=17 Participants	1 Participants n=10 Participants	0 Participants n=18 Participants	0 Participants n=3 Participants	0 Participants n=27 Participants	0 Participants n=4 Participants	4 Participants n=155 Participants
Education, years	12.45 Years STANDARD_DEVIATION 1.695 • n=11 Participants	13.92 Years STANDARD_DEVIATION 1.782 • n=12 Participants	13.82 Years STANDARD_DEVIATION 1.722 • n=11 Participants	12.75 Years STANDARD_DEVIATION 1.165 • n=8 Participants	14.12 Years STANDARD_DEVIATION 1.764 • n=17 Participants	14.35 Years STANDARD_DEVIATION 2.548 • n=17 Participants	14.35 Years STANDARD_DEVIATION 1.967 • n=17 Participants	12.8 Years STANDARD_DEVIATION 1.033 • n=10 Participants	13.33 Years STANDARD_DEVIATION 1.847 • n=18 Participants	12 Years STANDARD_DEVIATION 1 • n=3 Participants	17.19 Years STANDARD_DEVIATION 1.777 • n=27 Participants	14.67 Years STANDARD_DEVIATION 1.155 • n=4 Participants	14.28 Years STANDARD_DEVIATION 2.304 • n=155 Participants
Schizophrenia, schizoaffective diagnosis Schizophrenia disorder	3 participants n=11 Participants	4 participants n=12 Participants	4 participants n=11 Participants	6 participants n=8 Participants	0 participants n=17 Participants	0 participants n=17 Participants	0 participants n=17 Participants	0 participants n=10 Participants	9 participants n=18 Participants	1 participants n=3 Participants	0 participants n=27 Participants	0 participants n=4 Participants	27 participants n=155 Participants
Schizophrenia, schizoaffective diagnosis Schizoaffective disorder	8 participants n=11 Participants	8 participants n=12 Participants	7 participants n=11 Participants	2 participants n=8 Participants	0 participants n=17 Participants	0 participants n=17 Participants	0 participants n=17 Participants	0 participants n=10 Participants	9 participants n=18 Participants	2 participants n=3 Participants	0 participants n=27 Participants	0 participants n=4 Participants	36 participants n=155 Participants
PANSS Positive	12.09 units on a scale STANDARD_DEVIATION 3.91 • n=11 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	12.83 units on a scale STANDARD_DEVIATION 3.74 • n=12 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	12.82 units on a scale STANDARD_DEVIATION 3.34 • n=11 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	15.88 units on a scale STANDARD_DEVIATION 4.88 • n=8 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	—	—	—	—	13.11 units on a scale STANDARD_DEVIATION 3.31 • n=18 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	15.0 units on a scale STANDARD_DEVIATION 2.65 • n=3 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	—	—	13.01 units on a scale STANDARD_DEVIATION 3.73 • n=63 Participants • Measure only collected for subjects with SCZ and SCZ-CUD
PANSS Negative	15.82 units on a scale STANDARD_DEVIATION 8.34 • n=11 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	12.0 units on a scale STANDARD_DEVIATION 4.41 • n=12 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	15.09 units on a scale STANDARD_DEVIATION 7.91 • n=11 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	13.63 units on a scale STANDARD_DEVIATION 3.54 • n=8 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	—	—	—	—	14.61 units on a scale STANDARD_DEVIATION 3.96 • n=18 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	17.66 units on a scale STANDARD_DEVIATION 6.81 • n=3 Participants • Measure only collected for subjects with SCZ and SCZ-CUD	—	—	14.19 units on a scale STANDARD_DEVIATION 5.6 • n=63 Participants • Measure only collected for subjects with SCZ and SCZ-CUD
Days of Cannabis Use in Past 35	10.73 Days STANDARD_DEVIATION 9.30 • n=11 Participants	16.92 Days STANDARD_DEVIATION 10.10 • n=12 Participants	16.64 Days STANDARD_DEVIATION 10.96 • n=11 Participants	18.25 Days STANDARD_DEVIATION 14.76 • n=8 Participants	29.76 Days STANDARD_DEVIATION 10.14 • n=17 Participants	25.18 Days STANDARD_DEVIATION 12.86 • n=17 Participants	24.24 Days STANDARD_DEVIATION 11.55 • n=17 Participants	28.2 Days STANDARD_DEVIATION 10.35 • n=10 Participants	0 Days STANDARD_DEVIATION 0 • n=18 Participants	0 Days STANDARD_DEVIATION 0 • n=3 Participants	0.037 Days STANDARD_DEVIATION 0.192 • n=27 Participants	0.5 Days STANDARD_DEVIATION 1 • n=4 Participants	14.85 Days STANDARD_DEVIATION 15.54 • n=155 Participants
Number of Joints Smoked in Past 35 days	18.41 Number of Joints STANDARD_DEVIATION 26.99 • n=11 Participants	22.19 Number of Joints STANDARD_DEVIATION 18.82 • n=12 Participants	19.70 Number of Joints STANDARD_DEVIATION 16.01 • n=11 Participants	44.09 Number of Joints STANDARD_DEVIATION 62.20 • n=8 Participants	39.4 Number of Joints STANDARD_DEVIATION 45.3 • n=17 Participants	52.2 Number of Joints STANDARD_DEVIATION 78.6 • n=17 Participants	52.2 Number of Joints STANDARD_DEVIATION 57.5 • n=17 Participants	44.8 Number of Joints STANDARD_DEVIATION 51.2 • n=10 Participants	0 Number of Joints STANDARD_DEVIATION 0 • n=18 Participants	0 Number of Joints STANDARD_DEVIATION 0 • n=3 Participants	0.0357 Number of Joints STANDARD_DEVIATION 0.188 • n=27 Participants	0.333 Number of Joints STANDARD_DEVIATION 0.577 • n=4 Participants	26.01 Number of Joints STANDARD_DEVIATION 43.45 • n=155 Participants

PRIMARY outcome

Timeframe: 3 hours

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=11 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=18 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only n=17 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only n=17 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only n=17 Participants This group of subjects did not have CUD and received no intervention	Healthy Controls n=27 Participants This group of healthy subjects had no illness and received no intervention
Brain Reward Circuit Activation on fMRI Scan	0.05 z-score Standard Deviation 0.098	0.14 z-score Standard Deviation 0.076	0.18 z-score Standard Deviation 0.127	0.12 z-score Standard Deviation 0.058	0.10 z-score Standard Deviation 0.087	0.11 z-score Standard Deviation 0.081	0.17 z-score Standard Deviation 0.094	0.17 z-score Standard Deviation 0.121

PRIMARY outcome

Timeframe: 1 hour after smoking study drug, 3 hours after oral dronabinol

Population: Data was collected but cannot be compiled and analysis could not be completed due to death of PI and resulting limited resources for scan data compilation and analyses. There are no immediate resources for analysis in the future.

Resting state connectivity within brain reward circuitry as measured with the Fisher-transformed r value of the connectivity maps between the nucleus accumbans and other brain areas. The Fisher-transformation creates a normally distributed correlation value for statistical analyses assessing between group differences (smoked THC vs placebo; oral dronabinol vs placebo)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 3 hours after oral THC/placebo

Population: Only participants with Schizophrenia were assessed using the Positive and Negative Symptom Scale, as specified in the Study Protocol

Positive and Negative Symptom Scale (PANSS) Positive Symptom Mean Subscale Score at 2nd Assessment Day, range 7-49, higher = more symptoms. The outcome measure was recorded at single time of measurement. The time frame includes 3 hours after oral THC/placebo and 1 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=11 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=18 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only This group of subjects did not have CUD and received no intervention	Healthy Controls This group of healthy subjects had no illness and received no intervention
PANSS Positive Symptoms	11.0 score on a scale Standard Error 0.54	9.3 score on a scale Standard Error 0.40	10.2 score on a scale Standard Error 0.56	10.6 score on a scale Standard Error 0.37	—	—	—	—

SECONDARY outcome

Timeframe: 3 hours after oral THC/placebo

Population: This analysis tested whether the marijuana cigarette group had different PANSS negative symptom scores compared to the placebo group adjusting for the SCZ only group. (The dronabinol group was tested separately per our analytic plan.). Only participants with Schizophrenia were assessed using the Positive and Negative Symptom Scale, as specified in the Study Protocol.

Positive and Negative Symptom Scale Negative Symptom Mean Subscale Score at 2nd Assessment Day, range 7-49, higher = more symptoms. The time frame includes 3 hours after oral THC/placebo and 1 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=9 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=18 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only This group of subjects did not have CUD and received no intervention	Healthy Controls This group of healthy subjects had no illness and received no intervention
PANSS Negative Symptoms	17.1 score on a scale Standard Error 0.76	16.4 score on a scale Standard Error 0.67	15.8 score on a scale Standard Error 0.81	15.2 score on a scale Standard Error 0.56	—	—	—	—

SECONDARY outcome

Timeframe: 4 hours after oral drug

Cognitive functioning, verbal learning Hopkins Verbal Learning Test (HVLT-R) total raw score. Possible range of scores is 0-35, higher is better functioning. The time frame includes 4 hours after oral THC/placebo and 2 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=9 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=17 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only n=16 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only n=16 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only n=18 Participants This group of subjects did not have CUD and received no intervention	Healthy Controls n=27 Participants This group of healthy subjects had no illness and received no intervention
Cognitive Functioning, Verbal Learning	23.2 score on a scale Standard Deviation 6.8	21.8 score on a scale Standard Deviation 6.7	25.0 score on a scale Standard Deviation 5.0	25.0 score on a scale Standard Deviation 4.97	25.3 score on a scale Standard Deviation 6.1	27.9 score on a scale Standard Deviation 4.5	25.5 score on a scale Standard Deviation 8.6	31.0 score on a scale Standard Deviation 3.3

SECONDARY outcome

Timeframe: 3 hours after taking oral drug

Population: Only participants with Schizophrenia and CUD who were given study drug were analyzed for drug experiences, as specified in the Study Protocol

Drug experience ratings of mood and desirability, anxiety rating on a scale of 0-100, higher means more anxiety. The time frame includes 3 hours after oral THC/placebo and 1 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=10 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=18 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only This group of subjects did not have CUD and received no intervention	Healthy Controls This group of healthy subjects had no illness and received no intervention
Drug Experience, Anxiety	10.03 units on a scale Standard Deviation 4.64	3.88 units on a scale Standard Deviation 2.06	3.96 units on a scale Standard Deviation 2.30	14.31 units on a scale Standard Deviation 4.72	—	—	—	—

SECONDARY outcome

Timeframe: 3 hours after taking oral drug

Population: Only participants with Schizophrenia and CUD who were given study drug were analyzed for drug experiences, as specified in the Study Protocol

Drug experience ratings of liking rating on a scale of 0-100, higher number = more liking The time frame includes 3 hours after oral THC/placebo and 1 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=10 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only This group of subjects did not have CUD and received no intervention	Healthy Controls This group of healthy subjects had no illness and received no intervention
Drug Experience Ratings of Drug Liking	56.5 units on a scale Standard Error 21.66	56.36 units on a scale Standard Error 20.10	5.54 units on a scale Standard Error 3.49	—	—	—	—	—

SECONDARY outcome

Timeframe: 4 hours after oral drug

Cognitive function, CPT-IP 2 digit measure of Attention. The Continuous Performance Test-Identical Pairs version (CPT-IP)80 assessed attention with range of 1-5, hirer scores indicating better function The outcome measure was recorded at single time of measurement. The time frame includes 4 hours after oral THC/placebo and 2 hour after smoked THC/placebo (the three-hour window is inclusive of the one-hour post smoke). Each individual smoked THC or placebo AND took oral THC or placebo.

Outcome measures

Outcome measures
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=11 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette. SCZ-CUD n=12 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	Marijuana cigarette and placebo capsule CUD only n=17 Participants 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette CUD only n=17 Participants Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. CUD only n=17 Participants Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ only n=18 Participants This group of subjects did not have CUD and received no intervention	Healthy Controls n=27 Participants This group of healthy subjects had no illness and received no intervention
Cognitive Function, CPT-IP 2 Digit	3.5 score on a scale Standard Deviation 0.7	3.3 score on a scale Standard Deviation 0.9	3.7 score on a scale Standard Deviation 0.7	4.1 score on a scale Standard Deviation 0.4	3.8 score on a scale Standard Deviation 0.5	3.9 score on a scale Standard Deviation 0.4	3.2 score on a scale Standard Deviation 1.0	4.0 score on a scale Standard Deviation 0.3

Adverse Events

Marijuana cigarette and placebo capsule SCZ-CUD

Serious events: 1 serious events

Other events: 9 other events

Deaths: 0 deaths

Dronabinol and placebo cigarette SCZ-CUD

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Placebo cigarette and placebo capsule. SCZ-CUD

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

SCZ-CUD not randomized

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Marijuana cigarette and placebo capsule CUD only

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Dronabinol and placebo cigarette CUD only

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Placebo cigarette and placebo capsule CUD only

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Cannabis Use Disorder - CUD Did not randomize

Serious events: 1 serious events

Other events: 5 other events

Deaths: 0 deaths

SCZ only

Serious events: 2 serious events

Other events: 13 other events

Deaths: 0 deaths

SCZ only - Did not complete Scan 2

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Healthy Control -

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Healthy Control - Did not complete Scan 2

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=11 participants at risk 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette SCZ-CUD n=12 participants at risk Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 participants at risk Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ-CUD not randomized n=8 participants at risk Dual diagnosis of Schizophrenia and Cannabis Use disorder, - Completed Scan 1 but not Randomized	Marijuana cigarette and placebo capsule CUD only n=17 participants at risk CUD only 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant	Dronabinol and placebo cigarette CUD only n=17 participants at risk CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.	Placebo cigarette and placebo capsule CUD only n=17 participants at risk CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.	Cannabis Use Disorder - CUD Did not randomize n=10 participants at risk Cannabis Use Disorder (CUD), Completed Scan 1 but not Randomized	SCZ only n=18 participants at risk No drug intervention - Completed Scan 1 and 2	SCZ only - Did not complete Scan 2 n=3 participants at risk No drug intervention - Completed Scan 1 but not Scan 2	Healthy Control - n=27 participants at risk No drug intervention - Completed Scan 1 and 2	Healthy Control - Did not complete Scan 2 n=4 participants at risk No drug intervention - Completed Scan 1 but not Scan 2
Psychiatric disorders Psychosis	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	12.5% 1/8 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Vyvanse Intoxication	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Injury, poisoning and procedural complications Injury	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Hallucinations	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders Chest Pain	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)

Other adverse events

Other adverse events
Measure	Marijuana cigarette and placebo capsule SCZ-CUD n=11 participants at risk 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant with THC	Dronabinol and placebo cigarette SCZ-CUD n=12 participants at risk Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI. Dronabinol: Capsule with THC	Placebo cigarette and placebo capsule. SCZ-CUD n=11 participants at risk Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Placebo: Capsule with no active ingredient	SCZ-CUD not randomized n=8 participants at risk Dual diagnosis of Schizophrenia and Cannabis Use disorder, - Completed Scan 1 but not Randomized	Marijuana cigarette and placebo capsule CUD only n=17 participants at risk CUD only 3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI. Marijuana: Smoked plant	Dronabinol and placebo cigarette CUD only n=17 participants at risk CUD only Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.	Placebo cigarette and placebo capsule CUD only n=17 participants at risk CUD only Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.	Cannabis Use Disorder - CUD Did not randomize n=10 participants at risk Cannabis Use Disorder (CUD), Completed Scan 1 but not Randomized	SCZ only n=18 participants at risk No drug intervention - Completed Scan 1 and 2	SCZ only - Did not complete Scan 2 n=3 participants at risk No drug intervention - Completed Scan 1 but not Scan 2	Healthy Control - n=27 participants at risk No drug intervention - Completed Scan 1 and 2	Healthy Control - Did not complete Scan 2 n=4 participants at risk No drug intervention - Completed Scan 1 but not Scan 2
Psychiatric disorders Increased cannabis withdrawal symptoms	27.3% 3/11 • Number of events 6 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Psychiatric symptoms	18.2% 2/11 • Number of events 3 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	27.3% 3/11 • Number of events 3 • Since past assessment (1-2 weeks)	12.5% 1/8 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders Tachycardia	18.2% 2/11 • Number of events 2 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	35.3% 6/17 • Number of events 6 • Since past assessment (1-2 weeks)	17.6% 3/17 • Number of events 3 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders hypertension	0.00% 0/11 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Gastrointestinal disorders Dental Issues	9.1% 1/11 • Number of events 2 • Since past assessment (1-2 weeks)	25.0% 3/12 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Musculoskeletal and connective tissue disorders Pain in extremity	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Anxiety in MRI	9.1% 1/11 • Number of events 2 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 2 • Since past assessment (1-2 weeks)	33.3% 1/3 • Number of events 1 • Since past assessment (1-2 weeks)	7.4% 2/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Skin and subcutaneous tissue disorders Skin irritation	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Musculoskeletal and connective tissue disorders Back, shoulder or neck pain	9.1% 1/11 • Number of events 2 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	11.1% 2/18 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Nervous system disorders Headache	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 2 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	16.7% 3/18 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	14.8% 4/27 • Number of events 8 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Nervous system disorders MRI Finding - Nervous System	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	17.6% 3/17 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	22.2% 4/18 • Number of events 4 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	7.4% 2/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders Chest Pain	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Gastrointestinal disorders Nausea or vomiting	0.00% 0/11 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	9.1% 1/11 • Number of events 1 • Since past assessment (1-2 weeks)	12.5% 1/8 • Number of events 2 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Injury, poisoning and procedural complications Injury	0.00% 0/11 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	16.7% 3/18 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 3 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Respiratory, thoracic and mediastinal disorders Upper Respiratory Infection	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	27.3% 3/11 • Number of events 4 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 4 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	11.1% 2/18 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	14.8% 4/27 • Number of events 4 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Surgical and medical procedures Hemorrhoids	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Eye disorders Chalazia	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders Abnormal EKG	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Nervous system disorders Lightheaded/Dizzy	0.00% 0/11 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	11.1% 2/18 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	7.4% 2/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Nervous system disorders Dysesthesia/Parasthesia	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Ear and labyrinth disorders Ear pain	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Gastrointestinal disorders Hemorrhoids	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	3.7% 1/27 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Metabolism and nutrition disorders Hypoglycemia	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Cardiac disorders Hypotension	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Infections and infestations Skin infection	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Musculoskeletal and connective tissue disorders Muscle aches	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Vascular disorders MRI Findings - Vascular	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Respiratory, thoracic and mediastinal disorders MRI Findings - Respiratory	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/12 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	7.4% 2/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Vascular disorders Swelling of vein	0.00% 0/11 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Nervous system disorders Other	0.00% 0/11 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	12.5% 1/8 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	0.00% 0/18 • Since past assessment (1-2 weeks)	0.00% 0/3 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Hallucinations	27.3% 3/11 • Number of events 3 • Since past assessment (1-2 weeks)	8.3% 1/12 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/11 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/17 • Since past assessment (1-2 weeks)	0.00% 0/10 • Since past assessment (1-2 weeks)	11.1% 2/18 • Number of events 2 • Since past assessment (1-2 weeks)	33.3% 1/3 • Number of events 1 • Since past assessment (1-2 weeks)	0.00% 0/27 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)
Psychiatric disorders Anxiety	27.3% 3/11 • Number of events 3 • Since past assessment (1-2 weeks)	16.7% 2/12 • Number of events 2 • Since past assessment (1-2 weeks)	18.2% 2/11 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/8 • Since past assessment (1-2 weeks)	23.5% 4/17 • Number of events 4 • Since past assessment (1-2 weeks)	11.8% 2/17 • Number of events 3 • Since past assessment (1-2 weeks)	5.9% 1/17 • Number of events 1 • Since past assessment (1-2 weeks)	10.0% 1/10 • Number of events 1 • Since past assessment (1-2 weeks)	5.6% 1/18 • Number of events 1 • Since past assessment (1-2 weeks)	33.3% 1/3 • Number of events 1 • Since past assessment (1-2 weeks)	7.4% 2/27 • Number of events 2 • Since past assessment (1-2 weeks)	0.00% 0/4 • Since past assessment (1-2 weeks)

Additional Information

Dr. Mary F. Brunette

Dartmouth Hitchcock

Phone: 603-646-7019

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place